What Limits Sterile Filtration Throughput in 6% w/v HES 200/0.5 Injection Solutions?

Hydroxyethyl starch 200/0.5 is a branched amylopectin-derived polymer with a weight-average molecular weight of 200 000 Da and a molar substitution of 0.5. In injectable plasma volume expansion, the API is dissolved at 60 g/L in 0.9% w/v sodium chloride to produce a colloid osmotic pressure of approximately 36 mmHg at 37 °C. The manufacturing sequence begins with dissolution in WFI at 40–50 °C under low-shear agitation, followed by pH adjustment to 4.5–5.5 with 1 M sodium hydroxide or hydrochloric acid. The solution is filtered through a 0.45 µm prefilter and a 0.22 µm polyethersulfone final filter before terminal moist-heat sterilisation at 121 °C for 15 min per Ph. Eur. 5.1.1. The terminal finished product is a sterile, pyrogen-free intravenous infusion packaged in 250 mL or 500 mL flexible polyolefin bags.

Filterability is the principal processing conflict at production scale. The high molecular weight and branched structure of HES 200/0.5 increase solution viscosity, which reduces membrane flux and shortens filter train service life. A 6% w/v solution typically falls in the range 4.0–8.0 mPa·s at 20 °C when measured by Ph. Eur. 2.2.9, though the exact value depends on batch molecular-weight distribution. Filtration trials should therefore be performed on each API lot before scale-up; published data for filter sizing under terminal sterilisation of this specific configuration is limited. Filter inlet pressure should not exceed 1.0 bar, and the filtration train should be staged with hydrophilic membrane area sufficient to maintain a throughput margin above 20 L/m² at 20 °C for the first 30 min of filtration. The compliance matrix for injectable release is summarised below.

Operational boundaries for the injectable application are defined by regulatory contraindications rather than formulation incompatibility. HES 200/0.5 must not be used in patients with sepsis, severe renal impairment with creatinine clearance below 30 mL/min, or severe coagulopathy. Renal function should be monitored for at least 90 days after infusion. The solution should be stored at 15–25 °C and protected from freezing, because freeze-thaw cycling can destabilise the colloid and create visible particulate formation.

During the freezing stage of parenteral lyophilisation, hydroxyethyl starch 200/0.5 partitions into the freeze-concentrated liquid phase and functions as an amorphous cake stabiliser and crystallisation inhibitor. The API is dissolved in Water for Injections at 2.0–5.0% w/v together with the active substance and, where required, 2.0–5.0% w/v mannitol or glycine as crystalline bulking agents. The pre-lyophilisation solution is filtered through 0.22 µm filters, filled into Type I glass vials, and partially stoppered before loading into a lyophiliser. Cycle development begins with differential scanning calorimetry and freeze-dry microscopy to measure the collapse temperature of the formulation; primary drying shelf temperature is set 2–3 °C below the measured collapse temperature, and chamber pressure is controlled at 0.05–0.15 mbar. Secondary drying is performed at 25–30 °C for 6–12 h until residual moisture by Ph. Eur. 2.9.24 is ≤ 3.0% w/w. The terminal finished product is a lyophilised powder for injection that is reconstituted with WFI before administration.

Lyophilised parenteral matrices containing HES 200/0.5 must meet Ph. Eur. 2.9.1 appearance, Ph. Eur. 2.9.3 sub-visible particulate contamination after reconstitution, and USP <1> Injections for sterility and absence of pyrogens. A processing boundary governs thermal exposure before lyophilisation: the prepared solution should not be heated above 60 °C for more than 30 min, because excessive thermal treatment can shift the molecular-weight distribution and reduce the protective effect of the polymer during freezing. In production, batch-to-batch variance in molecular weight can alter the freeze-concentrate glass transition and collapse behaviour, so each new API lot should be subjected to a formulation-specific thermal characterisation before full-scale lyophilisation.

Wet-Granulation Binder Solution Viscosity and Atomised Spray Drying

In oral tablet manufacture, hydroxyethyl starch 200/0.5 is dissolved in purified water at 5.0–10.0% w/w to prepare a binder solution for high-shear wet granulation. The solution is sprayed onto a premixed dry blend of active pharmaceutical ingredient, lactose monohydrate and croscarmellose sodium to achieve 2.0–5.0% w/w HES in the final dry granule. The granulation is carried out in a high-shear mixer with impeller tip speed 5–8 m/s and chopper speed 1 500–2 500 rpm. Spray rate is held at 40–80 g/min per 10 kg dry blend to limit local overwetting. The wet mass is passed through a 1.25 mm screen, dried in a fluid-bed dryer with inlet air at 55–65 °C to a loss-on-drying value of ≤ 2.0% w/w, and then milled through an 800 µm screen. The dried granules are blended with 0.5% w/w magnesium stearate and compressed on a rotary tablet press to hardness 60–100 N. Tablets are tested for disintegration time ≤ 15 min and friability ≤ 1.0% by Ph. Eur. 2.9.7.

The binder solution must be monitored by Ph. Eur. 2.2.9, because viscosity directly determines spray droplet size and granule growth uniformity. If solution viscosity exceeds the range suitable for the spray nozzle, atomisation becomes coarse and granule size distribution widens, producing tablet content uniformity failures under USP <905> and dissolution variability under USP <711>. This imparts an operational boundary: high-molecular-weight HES 200/0.5 should not be used as a binder in high-shear equipment without prior nozzle compatibility testing, and moisture-sensitive actives should be excluded from aqueous granulation using this polymer because the required drying time can extend exposure to water at elevated temperature. The terminal finished product is a film-coated or uncoated immediate-release tablet.

When direct compression is ruled out by poorly flowing active ingredients or high-dose capsule fill weights, hydroxyethyl starch 200/0.5 is introduced in a top-spray fluid-bed granulation process as an aqueous binder at 3.0–7.0% w/w of the final filled capsule mass. The binder solution is prepared at 5.0% w/w in purified water and sprayed at 1.5–2.5 bar atomising air pressure, with inlet air temperature 50–60 °C and product temperature 35–45 °C, until granules reach a moisture content ≤ 2.5% w/w. The dried granules are sieved through a 1.0 mm mesh, lubricated with 0.5% w/w sodium stearyl fumarate, and filled into hard gelatin or HPMC capsules to a fill-weight variation within ± 5% of target. Capsule content uniformity is verified by USP <905>, in vitro release by USP <711>, and mass uniformity by Ph. Eur. 2.9.5. The terminal finished product is an immediate-release hard capsule.

The operational limitation of this capsule-granulation route is moisture sorption. HES 200/0.5 granules should be filled at ambient relative humidity below 40%; if ambient RH exceeds 60%, the granules should be pre-dried at 60 °C before filling because moisture uptake can produce sticking in capsule filling equipment and alter dissolution release. The process is therefore best suited to high-speed capsule filling lines equipped with environmental humidity control and gravimetric fill monitoring.

Hydrophilic Matrix Formation Depends on Granule Porosity and Pore Tortuosity

Hydroxyethyl starch 200/0.5 can be employed as a hydrophilic matrix former in oral sustained-release prototypes at 10–30% w/w of the granule core. The polymer hydrates on contact with dissolution fluid to form a gel layer in which drug release is controlled by combined diffusion and erosion. Published data for this specific molecular weight and molar substitution configuration is limited, so prototype screening is required before scale-up. Matrix granules are prepared by high-shear or fluid-bed granulation, dried to a loss-on-drying value ≤ 2.0% w/w, and compressed or filled into hard capsules. Dissolution testing is conducted using USP <711> Apparatus 2 at 50 rpm in 900 mL phosphate buffer pH 6.8 at 37 °C, with sampling at 1, 2, 4, 6, 8, 12, and 24 h. Compliance with content uniformity is assessed by USP <905>, and stability by ICH Q1A(R2). The terminal finished product is a sustained-release tablet or capsule, or an oral granule bed filled into a single-dose sachet where the granule structure controls release in suspension.

Formulation of sustained-release matrices from HES 200/0.5 is constrained by the polymer’s high swelling capacity and molecular weight. The matrix should not be compressed to porosity below 10%, because overly dense matrices can generate internal gel pressure that causes surface cracking and burst release. Conversely, porosity above 25% may allow premature erosion and loss of zero-order release character. These boundaries require granule compression profiles to be mapped against dissolution data for each drug-polymer ratio, rather than transferred directly from other hydrophilic matrix polymers such as hypromellose or polyethylene oxide.